In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...
All content for Market Access Matters is the property of Access Infinity and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...
Digitalisation of Market Access with Thomas Gilboy and Shravani Madishetti
Market Access Matters
24 minutes
1 year ago
Digitalisation of Market Access with Thomas Gilboy and Shravani Madishetti
In this special episode, Louise teams up with colleagues Thomas Gilboy and Shravani Madishetti from Access Infinity to explore the transformative impact of digital on market access. Shravani, APAC Pricing and Market Access Lead, highlights the efficiency and accuracy achieved through digital tools while Tom, Product Owner for Nuro, emphasises the importance of maximising the effectiveness of digital tools. Together, they offer valuable insights and practical guidance for navigating this evolv...
Market Access Matters
In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ...
